Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism

Journal of Internal Medicine

Volumn 277, Issue 6, 2015, Pages 707-716

  Vuilleumier, N ^a   Limacher, A ^b   Mean M ^b   Choffat, J ^a   Lescuyer, P ^a   Bounameaux, H ^a   Aujesky, D ^b   Righini, M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aged; Biochemical markers; NT proBNP; Prognosis; Pulmonary embolism; Troponin

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIAC TROPONIN T; TROPONIN T; UNCLASSIFIED DRUG; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; BLEEDING; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENEVA PROGNOSTIC SCORE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LOW RISK PATIENT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; PULMONARY EMBOLISM SEVERITY INDEX; RECURRENT DISEASE; REFERENCE VALUE; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SWISS; VENOUS THROMBOEMBOLISM; BLOOD; CLINICAL TRIAL; FOLLOW UP; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; PULMONARY EMBOLISM; RISK FACTOR; SWITZERLAND; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SWITZERLAND; TROPONIN T;

EID: 84929631128     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12316     Document Type: Article

References (26)

1. Torbicki A, Perrier A, Konstantinides S et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-315.
2. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with deltaparin. Thromb Haemost 2000; 83: 209-11.
3. Beer JH, Burger M, Gretener S, Bernard Bagattini S, Bounameaux H. Outpatients treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost 2003; 1: 186-7.
4. Aujesky D, Roy PM, Verschuren F et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378: 41-8.
5. Goldhaber SZ, Eliott CG. Acute pulmonary embolism, II: risk stratification, treatment, and prevention. Circulation 2003; 108: 2834-8.
6. Agterof MJ, Schutgens RE, Snijder RJ et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010; 8: 1235-41.
7. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost effectiveness of low molecular heparin for treatment of pulmonary embolism. Chest 2005; 128: 1601-10.
8. Nendaz MR, Bandelier P, Aujesky D et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 2004; 91: 1232-6.
9. Coutance G, Le Page O, Lo T, Hamon M. Prognostic value of brain natriuretic peptide in acute pulmonary embolism. Crit Care 2008; 12: R109.
10. Vuilleumier N, Le Gal G, Verschuren F et al. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 2009; 7: 391-8.
11. Lankeit M, Friesen D, Aschoff J et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31: 1836-44.
12. Lankeit M, Jiménez D, Kostrubiec M et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124: 2716-24.
13. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5: 599-606.
14. Chenevier-Gobeaux C, Meune C, Freund Y et al. Influence of age and renal function on high-sensitivity cardiac troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction. Am J Cardiol 2013; 111: 1701-7.
15. Zwierzina D, Limacher A, Méan M et al. Prospective comparison of clinical prognostic scores in elderly patients with pulmonary embolism. J Thromb Haemost 2012; 10: 2270-6.
16. Méan M, Righini M, Jaeger K et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65 + ): rationale and methodology. J Thromb Thrombolysis 2013; 36: 484-91.
17. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 548-52.
18. Apple FS, Jaffe AS. Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: user beware. Clin Chem 2012; 58: 1599-600.
19. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581-98.
20. Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 15: 948-54.
21. deFilippi C, Seliger SL, Kelley W et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem 2012; 58: 1342-51.
22. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminalpro-B-type natriuretic peptide for predicting coronary disease and leftventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46: 35-44.
23. Zoccali C, Mallamaci F, Benedetto FA et al. Cardiac natriuretic peptides are related to left ventricular mass andfunction and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-15.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72.
26. Lankeit M, Jiménez D, Kostrubiec M et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43: 1669-77.